Next Article in Journal
Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, Body Composition, and Heart Rate Variability
Next Article in Special Issue
Liquid and Vapor Phase of Four Conifer-Derived Essential Oils: Comparison of Chemical Compositions and Antimicrobial and Antioxidant Properties
Previous Article in Journal
Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
Previous Article in Special Issue
Antimicrobial Peptide K11 Selectively Recognizes Bacterial Biomimetic Membranes and Acts by Twisting Their Bilayers
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Review

Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

1
Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA 94103, USA
2
Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey
3
Department of Pharmacy Services, Vocational School of Health Services, Tarsus University, Mersin 33400, Turkey
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(1), 34; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010034
Received: 22 November 2020 / Revised: 25 December 2020 / Accepted: 29 December 2020 / Published: 5 January 2021
(This article belongs to the Special Issue Novel Antibacterial Agents)
Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii. View Full-Text
Keywords: lytic infection; antibiotic-resistance; Mycobacterium tuberculosis; Acinetobacter baumannii; Pseudomonas aeruginosa; phage production; magistral phage; pulmonary delivery; oral administration; topical delivery lytic infection; antibiotic-resistance; Mycobacterium tuberculosis; Acinetobacter baumannii; Pseudomonas aeruginosa; phage production; magistral phage; pulmonary delivery; oral administration; topical delivery
Show Figures

Figure 1

MDPI and ACS Style

Düzgüneş, N.; Sessevmez, M.; Yildirim, M. Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier. Pharmaceuticals 2021, 14, 34. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010034

AMA Style

Düzgüneş N, Sessevmez M, Yildirim M. Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier. Pharmaceuticals. 2021; 14(1):34. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010034

Chicago/Turabian Style

Düzgüneş, Nejat, Melike Sessevmez, and Metin Yildirim. 2021. "Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier" Pharmaceuticals 14, no. 1: 34. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010034

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop